Advertisement


Benjamin Besse, MD, PhD, and Tony Mok, MD, on Results of the BIRCH Clinical Trial

2015 European Cancer Congress

Advertisement

Benjamin Besse, MD, PhD, of the Institut Gustave Roussy, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss this phase II trial of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1–selected NSCLC (Abstract 17LBA).



Related Videos

Global Cancer Care

Christoph Zielinski, MD: Highlights of 2015 European Cancer Congress

As Chair of the ECC Local Organizing Committee, Christoph Zielinski, MD, of the Medical University Vienna - General Hospital, shares his thoughts on the important goals and presentations of the 2015 Congress.

Issues in Oncology

Ignacio Melero, MD, PhD, on Developing and Implementing New Immunotherapies

Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses the latest developments in an important cancer treatment avenue.

Bladder Cancer

Jonathan E. Rosenberg, MD, on Results of the IMvigor 210 Study on Atezolizumab in Locally Advanced or Metastatic Urothelial Cancer

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses this pivotal study of an investigational immunotherapy that has shown increased and durable responses, with a relatively benign toxicity profile (Abstract 21LBA).

Breast Cancer

Clifford A. Hudis, MD, on Results of the TAILORx Clinical Trial

Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discusses this prospective study of endocrine therapy alone in patients with ER-positive, HER2-negative, node-negative breast cancer (Abstract 5BA).

Issues in Oncology

Clifford A. Hudis, MD, on Obesity, Inflammation, and Cancer

Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, summarizes his educational lecture on obesity, inflammation, and cancer—an important topic in oncology.

Advertisement

Advertisement




Advertisement